Amgen (XSGO:AMGN) Current Accrued Expense : $14,127 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Amgen Current Accrued Expense?

Amgen's Current Accrued Expense for the quarter that ended in Mar. 2024 was $14,127 Mil.

Amgen's quarterly Current Accrued Expense declined from Sep. 2023 ($14,168 Mil) to Dec. 2023 ($11,109 Mil) but then increased from Dec. 2023 ($11,109 Mil) to Mar. 2024 ($14,127 Mil).

Amgen's annual Current Accrued Expense increased from Dec. 2021 ($7,324 Mil) to Dec. 2022 ($9,093 Mil) and increased from Dec. 2022 ($9,093 Mil) to Dec. 2023 ($11,109 Mil).

Amgen Current Accrued Expense Historical Data

The historical data trend for Amgen's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Current Accrued Expense Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

5,463.00

6,723.00

7,324.00

9,093.00

11,109.00

Amgen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															12,061.00	13,718.00	14,168.00	11,109.00	14,127.00

Amgen Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Amgen Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Amgen's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (XSGO:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (XSGO:AMGN) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMG:Germany AMG:Germany AMG:Germany AMGN34:Brazil AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.